Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

NCT04256707 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Carcinoma (NSCLC)
Colorectal Cancer (CRC)
Other Solid Tumors

Interventions

DRUG: Selinexor 100 mg
DRUG: Docetaxel
DRUG: Pembrolizumab
DRUG: FOLFIRI
DRUG: Selinexor 40 mg
DRUG: Selinexor 80 mg
DRUG: Selinexor 60 mg

Sponsor

Karyopharm Therapeutics Inc